Skip to Main Content

Advertisement

Skip Nav Destination

Transcription inhibition by Actinomycin D as a mechanism-based approach to treatment of Bcr-Abl-positive chronic myelogenous leukemia

Cancer Res (2007) 67 (9_Supplement): 3211.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal